📢 AACR 2025 Poster Alert! 📢 Join us at Poster #3993 to discover how Champions Oncology is transforming high-throughput screening for Antibody Drug Conjugate (ADC) payloads using a robust patient-derived 3D culture platform across 10+ cancer types. What you'll learn: 🔹 Miniaturized 384-well assay for efficient ADC payload testing 🔹 High fidelity 3D models representing real patient biology 🔹 Pharmacological insights supported by RNA expression and drug response correlation 📍 High-throughput screening of clinically relevant patient-derived 3D cultures to inform on the efficacy of Antibody Drug Conjugate Payloads in 10 distinct cancer indications 📆 Tuesday, April 29th, 2025 | 9am - 12pm 👉Add to your calendar: https://hubs.li/Q03jmKyg0 #AACR2025 #ChampionsOncology #3DModels #HighThroughputScreening #ADCs #PatientDerivedModels #CancerResearch #Pharmacology #PrecisionOncology #OrganoidScreening #TranslationalResearch #organoids
Champions Oncology, Inc.
Biotechnology
Hackensack, New Jersey 10,118 followers
US-based, End-to-End Oncology Pharmacology Solutions CRO
About us
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company’s Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient’s tumor, enabling them to better select treatment regimens.
- Website
-
http://www.championsoncology.com
External link for Champions Oncology, Inc.
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- Hackensack, New Jersey
- Type
- Public Company
- Founded
- 2007
- Specialties
- Translational Oncology Research, Personalized Oncology, Patient Derived Xenograft, Oncology Pharmacology, Immuno-Oncology, Flow Cytometry, Syngeneic Models, Humanized Mouse Models, Clinical Flow Cytometry, PDX, 3D Organoid Models, Clinical Specialty Testing, Hematological Modeling, Leukemia Models, GCLP, Cancer Vaccine Research, Preclinical Oncology Research, Global Clinical Trials, Ex Vivo Platforms, CDX, Cell Line Screening, Organoid Screening, Orthotopic Modeling, Computational Biology, Bioinformatics, Proteomics, and Multi-Omics
Locations
-
Primary
Get directions
Hackensack
Hackensack, New Jersey 07601, US
-
Get directions
1330 Piccard Dr
Suite 025 & 104
Rockville, Maryland 20850, US
-
Get directions
Via L. Ariosto 21, 1st Floor
Bresso MI, 20091, IT
-
Get directions
4 Oppenheimer St., Ha’ogen Building B
Rehovot, 7670104, IL
Employees at Champions Oncology, Inc.
Updates
-
Join us at the ASGCT 28th Annual Meeting and visit Poster #592 to learn how Champions Oncology in partnership with Taconic Biosciences is transforming AML immunotherapy research with a groundbreaking HLA-matched humanized in vivo model. Poster #592 Title: Development of a Humanized Immune System Mouse Supporting Primary AML PDX Engraftment for Drug Efficacy Studies 📅 Date: May 13, 2025 🕕 Time: 6:00 PM – 7:30 PM The poster highlights: 🔹 Development of a fully humanized immune system mouse model using CD34+ HSCs 🔹 Engraftment with never-passaged primary AML PDXs preserving tumor heterogeneity 🔹 Flow cytometry-based monitoring of AML progression and immune reconstitution 🔹 A novel platform for testing checkpoint inhibitors, CAR-T, and combination therapies in AML 📍 Discover how this innovative model is advancing preclinical testing of AML immunotherapies. #ASGCT2025 #ChampionsOncology #AML #ImmunoOncology #HumanizedModels #PDXModels #PreclinicalModels #CancerResearch #CD34 #HSC #CheckpointInhibitors #CAR_T
-
-
📢 AACR 2025 Poster Alert! 📢 Join us at Poster #5567 to see how Champions Oncology is advancing immunotherapy research in multiple myeloma (MM) with a powerful ex vivo and flow cytometry platform. The poster highlights: 🔹 Deep phenotyping of MM subsets across patient-derived samples and cell lines 🔹 A flexible “drop-in” flow cytometry panel for rapid biomarker discovery 🔹 Ex vivo drug sensitivity screening using refractory, relapsed, and naïve MM models 📍 Targeted Immunotherapies in Multiple Myeloma: Focus on Flow Cytometry Markers and Therapeutic Implications 📆 Tuesday, April 29th, 2025 | 2pm - 5 pm 👉Add to your calendar: https://hubs.li/Q03j0t_h0 #AACR25 #ChampionsOncology #MultipleMyeloma #Immunotherapy #FlowCytometry #ExVivoModels #BiomarkerDiscovery #CancerResearch #PreclinicalModels #HematologicMalignancies #AACR2025
-
-
📢 We’re honored to welcome one of the most recognized leaders in breast cancer research to AACR 2025! 🎯Join Champions Oncology at Booth #839 to meet Dr. Steffi Oesterreich, a globally respected expert with a dedicated focus on invasive lobular carcinoma (ILC)—a common yet often under-researched subtype of breast cancer. Her pioneering work is advancing our understanding of breast cancer biology, with the goal of improving treatment strategies and patient outcomes. Whether you're initiating or expanding your breast cancer pipeline, this is a unique opportunity to consult with a KOL driving progress in the field! 🗓️ Dr. Oesterreich will be available for 1:1 Meetings on Monday, April 28, 2025, from 9:00 AM to 11:00 AM. 👉Book your meeting here: https://hubs.li/Q03j0wW90 #BreastCancerResearch #InvasiveLobularCarcinoma #ILC #CancerBiology #PrecisionOncology #TranslationalResearch #AACR2025
-
-
📢 AACR 2025 Poster Alert! 📢 Visit us at Poster #3903 to discover how Champions Oncology and the University of Pittsburgh School of Medicine are uncovering new tools to advance research in Invasive Lobular Carcinoma (ILC)—a historically understudied breast cancer subtype. The poster highlights: 🔹 Identification of 7 ILC-specific PDX models via Champions’ Lumin multi-omics platform 🔹 Integrated genomic, transcriptomic, and histopathology assessment of ILC vs NST PDXs 🔹 Insights into unique molecular features and treatment implications for ILC 📍Multi-omics and histological assessment to identify patient-derived xenograft models of invasive lobular carcinoma 📆 Tuesday, April 29th, 2025 | 9am–12pm 📌 Add to your calendar: https://hubs.li/Q03h5cyx0 #AACR25 #ChampionsOncology #ILC #PDXModels #BreastCancerResearch #LuminPlatform #CancerGenomics #PrecisionOncology #TranslationalResearch
-
-
📢 AACR 2025 Poster Alert! 📢 Join us at Poster #7282 to explore how Champions Oncology, in collaboration with Taconic Biosciences, is transforming AML immunotherapy research with a groundbreaking HLA-matched humanized in vivo model. The poster highlights: 🔹 Development of a fully humanized immune system mouse model using CD34+ HSCs 🔹 Engraftment with never-passaged primary AML PDXs preserving tumor heterogeneity 🔹 Flow cytometry-based monitoring of AML progression and immune reconstitution 🔹 A novel platform for testing checkpoint inhibitors, CAR-T, and combo therapies in AML 📍 Development of an HLA-matched humanized immune system mouse model with primary AML patient samples for immunotherapy testing 📆 Wednesday, April 30th, 2025 | 9am - 12pm 👉Add to your calendar: https://hubs.li/Q03hYr2L0 #AACR25 #ChampionsOncology #AML #ImmunoOncology #HumanizedModels #PDXModels #PreclinicalModels #CancerResearch #CD34 #HSC #CheckpointInhibitors #CAR_T #AACR2025
-
-
✨Using Flow Cytometry as an In Vivo Study Endpoint✨ In a recent blog, we explore how incorporating flow cytometry as an endpoint in in vivo studies can unlock deeper insights into immune cell dynamics, tumor response, and overall treatment efficacy. If you're looking to elevate your oncology research with more meaningful data—this one's for you. 👉 Read our blog: https://hubs.li/Q03h5cyJ0 #FlowCytometry #OncologyResearch #InVivoModels #PreclinicalResearch #CancerResearch #ImmunoOncology
-
📢 AACR 2025 Poster Alert! 📢 Catch us at Poster #1287 to learn how our low-passage NSCLC PDX models are advancing the evaluation of c-MET–targeted therapies for EGFR-resistant tumors. The poster highlights: 🔹 A panel of clinically annotated NSCLC PDX models derived post-EGFR inhibitor treatment 🔹 Translational insights into c-MET ADC efficacy across EGFR mutant and wildtype models 🔹 Preserved tumor heterogeneity and molecular features for accurate preclinical evaluation 📍Clinical relevance and translatability of NSCLC patient-derived xenograft (PDX) models for evaluating cMET-targeted therapies 📆 Monday, April 28th, 2025 | 9am - 12pm Add to your calendar: https://hubs.li/Q03hSpbY0 #AACR25 #ChampionsOncology #NSCLC #PDXModels #cMET #TargetedTherapy #EGFRResistance #PreclinicalResearch #OncologyInnovation
-
-
📣We’re excited to welcome one of the most respected voices in radiopharmacy to AACR! 🎯Join Champions Oncology at Booth #839 to meet Dr. Shankar Vallabhajosula, a renowned expert with over four decades of groundbreaking work in nuclear medicine and investigational radiopharmaceuticals. His work bridges academic excellence and industry innovation, making him a trusted advisor to radiopharmaceuticals drug developers worldwide. Whether you're in early development or scaling a radiopharmaceutical pipeline, this is your chance to consult with a KOL who’s helped shape the field. 🗓️ Dr. Vallabhajosula will be available for one-on-one discussions on Sunday, April 27, 2025, from 2:00 PM to 5:00 PM. 📍 Book your meeting here: https://hubs.li/Q03hRgH_0 #Radiopharmaceuticals #AACR2025 #AACR #AACRAnnualMeeting #NuclearMedicine #Radiochemistry #Radiopharmacy #OncologyResearch #CancerDrugDevelopment #TargetedTherapies
-
-
We're #hiring a new Head of Radiopharmacology in Rockville, Maryland. Apply today or share this post with your network.